Felix J. M. Van Der Meer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Felix J. M. Van Der Meer has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
F. R. Rosendaal
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
4 shared publicationsFrits R. Rosendaal
Department of Thrombosis and Haemostasis, Leiden University Medical Centre
3 shared publications- Alain Gadisseur
Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
2 shared publications E. P. A. Gebuis
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
2 shared publicationsEva K. Rombouts
Department of Thrombosis and Haemostasis, Leiden University Medical Centre, Leiden, the Netherlands
2 shared publicationsW. M. Lijfering
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications
Latest Publications
- 25 June 2015
- Published by Springer Nature
- p. 307-328
Pharmacogenetics of Coumarin Anticoagulant Therapy
- 25 June 2015
- Published by Springer Nature
- p. 307-328
Pharmacogenetics of Coumarin Anticoagulant Therapy
- Open Access
- 10 October 2014
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 12 (12) , 2017-2023
Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects
- 10 October 2014
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 12 (12) , 2017-2023
Open AccessVitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects
- 1 June 2014
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 12 (6) , 887-890
Metformin use decreases the anticoagulant effect of phenprocoumon
- 1 June 2014
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 12 (6) , 887-890
Metformin use decreases the anticoagulant effect of phenprocoumon
- Open Access
- 18 January 2013
- Published by Springer Nature
A study to assess whether complications of anti-coagulation treatment with vitamin K antagonists will diminish by supplementation of vitamin K
- 18 January 2013
- Published by Springer Nature
Open AccessA study to assess whether complications of anti-coagulation treatment with vitamin K antagonists will diminish by supplementation of vitamin K
- Open Access
- 5 December 2012
- Published by Springer Nature
Low dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomised double-blind placebo controlled trial
- 5 December 2012
- Published by Springer Nature
Open AccessLow dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomised double-blind placebo controlled trial
- 29 December 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 96 (4) , 583-589
Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study
Background Poor anticoagulant stability in patients using vitamin K antagonists is a risk factor for both bleeding and thrombosis. In previous studies supplementation with low dose vitamin K1 was shown to improve the stability of anticoagulant control. We set up a study to confirm earlier reports and to determine the optimal daily dose of vitamin K1 in preparation of a large study with clinical endpoints. Design and Methods Four hundred patients from two anticoagulation clinics starting with vitamin K antagonists, independently of a possible history of instable anticoagulation, were randomized to receive either placebo or 100, 150 or 200 μg of vitamin K1 together with their treatment with vitamin K antagonists. The treatment was administered for 6 to 12 months. Anticoagulation stability, expressed as the percentage of time that the International Normalized Ratio was within the therapeutic range, was compared between the groups. Results After adjustment for age, sex, vitamin K antagonist used, anticoagulation clinic and interacting drugs as confounding factors the difference in percentage of time with the International Normalized Ratio within the therapeutic range between the placebo group and the vitamin K1 groups was 2.1% (95% CI: −3.2% – 7.4%) for the group taking 100 μg, 2.7% (95% CI: −2.3% –7.6%) for the group taking 150 μg and 0.9% (95% CI: −4.5% – 6.3%) for the group taking 200 μg vitamin K1 group, in favor of the vitamin K1 groups. The patients from both the 100 μg group and the 150 μg group had a 2-fold higher chance of reaching at least 85% of time with the International Normalized Ratio within the therapeutic range. There were no differences in thromboembolic or hemorrhagic complications between the groups. Conclusions In patients starting vitamin K antagonists, supplementation with low dose vitamin K1 resulted in an improvement of time that anticoagulation was within the therapeutic range. Differences between doses were, however, small and the improvement is unlikely to be of clinical relevance. For future studies we recommend selecting only patients with instable anticoagulant control. (This study was registered at www.isrctn.org as ISRCTN37109430)
- 29 December 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 96 (4) , 583-589
Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study
Background Poor anticoagulant stability in patients using vitamin K antagonists is a risk factor for both bleeding and thrombosis. In previous studies supplementation with low dose vitamin K1 was shown to improve the stability of anticoagulant control. We set up a study to confirm earlier reports and to determine the optimal daily dose of vitamin K1 in preparation of a large study with clinical endpoints. Design and Methods Four hundred patients from two anticoagulation clinics starting with vitamin K antagonists, independently of a possible history of instable anticoagulation, were randomized to receive either placebo or 100, 150 or 200 μg of vitamin K1 together with their treatment with vitamin K antagonists. The treatment was administered for 6 to 12 months. Anticoagulation stability, expressed as the percentage of time that the International Normalized Ratio was within the therapeutic range, was compared between the groups. Results After adjustment for age, sex, vitamin K antagonist used, anticoagulation clinic and interacting drugs as confounding factors the difference in percentage of time with the International Normalized Ratio within the therapeutic range between the placebo group and the vitamin K1 groups was 2.1% (95% CI: −3.2% – 7.4%) for the group taking 100 μg, 2.7% (95% CI: −2.3% –7.6%) for the group taking 150 μg and 0.9% (95% CI: −4.5% – 6.3%) for the group taking 200 μg vitamin K1 group, in favor of the vitamin K1 groups. The patients from both the 100 μg group and the 150 μg group had a 2-fold higher chance of reaching at least 85% of time with the International Normalized Ratio within the therapeutic range. There were no differences in thromboembolic or hemorrhagic complications between the groups. Conclusions In patients starting vitamin K antagonists, supplementation with low dose vitamin K1 resulted in an improvement of time that anticoagulation was within the therapeutic range. Differences between doses were, however, small and the improvement is unlikely to be of clinical relevance. For future studies we recommend selecting only patients with instable anticoagulant control. (This study was registered at www.isrctn.org as ISRCTN37109430)
- Open Access
- 25 April 2010
- Published by Wiley in British Journal of Haematology
- Vol. 149 (4) , 598-605
Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy
It is unclear what advice should be given to patients using vitamin K antagonists with respect to dietary vitamin K intake. We performed a nested case–control study in patients attending a Dutch anticoagulation clinic, to determine the association between vitamin K intake and subtherapeutic International Normalized Ratio (INR) values and the interaction between usual and recent vitamin K intake. Compared to patients with a normal usual vitamin K intake, those with a high vitamin K intake had a decreased risk of a subtherapeutic INR [Hazard Ratio (HR) 0·80, 95% confidence interval (CI): 0·56–1·16] and patients with a low vitamin K intake an increased risk (HR 1·33, 95% CI: 0·79–2·25). In patients with a low usual vitamin K intake, recent vitamin K intake was twice as high in cases as in controls (164 vs. 85 μg/d). Such a difference was not observed in patients with a normal or high usual vitamin K intake. Our results suggest that a high vitamin K intake reduces the risk of a low INR by lessening the influence of incidental consumption of vitamin K rich food on the INR. These findings support the recommendation for patients on vitamin K antagonists to eat a sufficient amount of vitamin‐K containing foods.
- 25 April 2010
- Published by Wiley in British Journal of Haematology
- Vol. 149 (4) , 598-605
Open AccessInfluence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy
It is unclear what advice should be given to patients using vitamin K antagonists with respect to dietary vitamin K intake. We performed a nested case–control study in patients attending a Dutch anticoagulation clinic, to determine the association between vitamin K intake and subtherapeutic International Normalized Ratio (INR) values and the interaction between usual and recent vitamin K intake. Compared to patients with a normal usual vitamin K intake, those with a high vitamin K intake had a decreased risk of a subtherapeutic INR [Hazard Ratio (HR) 0·80, 95% confidence interval (CI): 0·56–1·16] and patients with a low vitamin K intake an increased risk (HR 1·33, 95% CI: 0·79–2·25). In patients with a low usual vitamin K intake, recent vitamin K intake was twice as high in cases as in controls (164 vs. 85 μg/d). Such a difference was not observed in patients with a normal or high usual vitamin K intake. Our results suggest that a high vitamin K intake reduces the risk of a low INR by lessening the influence of incidental consumption of vitamin K rich food on the INR. These findings support the recommendation for patients on vitamin K antagonists to eat a sufficient amount of vitamin‐K containing foods.
- 1 January 2009
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 101 (03) , 552-556
Subtherapeutic oral anticoagulant therapy: Frequency and risk factors
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.
- 1 January 2009
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 101 (03) , 552-556
Subtherapeutic oral anticoagulant therapy: Frequency and risk factors
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.
- Open Access
- 31 July 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (10) , 2043-2048
Daily vitamin K supplementation improves anticoagulant stability
- 31 July 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (10) , 2043-2048
Open AccessDaily vitamin K supplementation improves anticoagulant stability